rspНаучно-практическая ревматологияRheumatology Science and Practice1995-44841995-4492IMA-PRESS, LLC10.47360/1995-4484-2023-70-76rsp-3280Research ArticleОБЗОРЫ И ЛЕКЦИИREVIEWS AND LECTURESМенопаузальная гормонотерапия при системной красной волчанке: pro et contraMenopausal hormone therapy in systemic lupus erythematosus: Pro et contrahttps://orcid.org/0000-0002-5290-156XПаневинТ. С.PanevinT. S.

Паневин Тарас Сергеевич115522, Российская Федерация, Москва, Каширское шоссе, 34а 

115522, Russian Federation, Moscow, Kashirskoye Highway, 34A 

tarasel@list.ruhttps://orcid.org/0000-0001-5793-4689ПопковаТ. В.PopkovaT. V.

115522, Российская Федерация, Москва, Каширское шоссе, 34а 

115522, Russian Federation, Moscow, Kashirskoye Highway, 34A 

https://orcid.org/0000-0003-3552-2522РешетнякТ. М.ReshetnyakT. M.

115522, Российская Федерация, Москва, Каширское шоссе, 34а 

115522, Russian Federation, Moscow, Kashirskoye Highway, 34A 

https://orcid.org/0000-0002-6018-3895КошелеваН. М.KoshelevaN. M.

115522, Российская Федерация, Москва, Каширское шоссе, 34а 

115522, Russian Federation, Moscow, Kashirskoye Highway, 34A 

https://orcid.org/0000-0001-6354-0475ЛединаА. В.LedinaA. V.

117198, Российская Федерация, Москва, ул. Миклухо-Маклая, 6 

117198, Russian Federation, Moscow, Miklukho-Maklaya str., 6 

ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»РоссияV.A. Nasonova Research Institute of RheumatologyRussian FederationФГАОУ ВО «Российский университет дружбы народов»РоссияPeople’s Friendship University of RussiaRussian Federation2023030320236117076Copyright © Паневин Т.С., Попкова Т.В., Решетняк Т.М., Кошелева Н.М., Ледина А.В., 20232023Паневин Т.С., Попкова Т.В., Решетняк Т.М., Кошелева Н.М., Ледина А.В.Panevin T.S., Popkova T.V., Reshetnyak T.M., Kosheleva N.M., Ledina A.V.This work is licensed under a Creative Commons Attribution 4.0 License.https://rsp.mediar-press.net/rsp/article/view/3280

Появление современных методов лечения системной красной волчанки (СКВ) привело к увеличению продолжительности и качества жизни пациентов с этим заболеванием. Вместе с тем большинство больных с СКВ – это женщины, и хорошо известно, что женские половые гормоны – эстрогены – могут оказывать влияние на активность системных аутоиммунных заболеваний, включая СКВ. Увеличение продолжительности жизни означает увеличение длительности пребывания женщины в постменопаузе с возможностью появления классических климактерических нарушений, развития или усугубления коморбидной патологии, в первую очередь остеопороза и сердечно-сосудистых заболеваний, а также необходимость повышения качества жизни женщин с этими заболеваниями. В настоящем обзоре собраны и проанализированы данные о риске и пользе применения менопаузальной гормональной терапии при СКВ.

The emergence of modern methods of treatment of systemic lupus erythematosus (SLE) has led to an increase in the duration and quality of life of patients with this disease. However, the majority of patients with SLE are women, and it is well known that the female sex hormone estrogen can influence the activity of systemic autoimmune diseases, including SLE. An increase in life expectancy means an increase in the length of a postmenopausal woman’s stay, with the possibility of the appearance of classic menopausal disorders, and the development or aggravation of comorbid pathologies, primarily osteoporosis and cardiovascular diseases, as well as the need to improve the quality of life for women with these diseases. This review collects and analyzes data on the risks and benefits of using menopausal hormone therapy for SLE.

системная красная волчанкаменопаузаэстрогеныменопаузальная гормонотерапияsystemic lupus erythematosusmenopauseestrogensmenopausal hormone therapyReferencesBorchers AT, Naguwa SM, Shoenfeld Y, Gershwin ME. The geoepidemiology of systemic lupus erythematosus. Autoimmun Rev. 2010;9(5):A277-A287. doi: 10.1016/j.autrev.2009.12.008Borchers AT, Naguwa SM, Shoenfeld Y, Gershwin ME. The geoepidemiology of systemic lupus erythematosus. Autoimmun Rev. 2010;9(5):A277-A287. doi: 10.1016/j.autrev.2009.12.008Mok CC, Lau CS, Wong RW. Use of exogenous estrogens in systemic lupus erythematosus. Semin Arthritis Rheum. 2001;30(6):426-435. doi: 10.1053/sarh.2001.22498Mok CC, Lau CS, Wong RW. Use of exogenous estrogens in systemic lupus erythematosus. Semin Arthritis Rheum. 2001;30(6):426-435. doi: 10.1053/sarh.2001.22498Stavrou I, Zois C, Ioannidis JP, Tsatsoulis A. Association of polymorphisms of the oestrogen receptor alpha gene with the age of menarche. Hum Reprod. 2002;17(4):1101-1105. doi: 10.1093/humrep/17.4.1101Stavrou I, Zois C, Ioannidis JP, Tsatsoulis A. Association of polymorphisms of the oestrogen receptor alpha gene with the age of menarche. Hum Reprod. 2002;17(4):1101-1105. doi: 10.1093/humrep/17.4.1101Johansson M, Arlestig L, Möller B, Smedby T, Rantapää-Dahlqvist S. Oestrogen receptor {alpha} gene polymorphisms in systemic lupus erythematosus. Ann Rheum Dis. 2005;64(11):1611-1617. doi: 10.1136/ard.2004.032425Johansson M, Arlestig L, Möller B, Smedby T, Rantapää-Dahlqvist S. Oestrogen receptor {alpha} gene polymorphisms in systemic lupus erythematosus. Ann Rheum Dis. 2005;64(11):1611-1617. doi: 10.1136/ard.2004.032425Boddaert J, Huong DLT, Amoura Z, Wechsler B, Godeau P, Piette JC. Late-onset systemic lupus erythematosus: a personal series of 47 patients and pooled analysis of 714 cases in the literature. Medicine (Baltimore). 2004;83(6):348-359. doi: 10.1097/01.md.0000147737.57861.7cBoddaert J, Huong DLT, Amoura Z, Wechsler B, Godeau P, Piette JC. Late-onset systemic lupus erythematosus: a personal series of 47 patients and pooled analysis of 714 cases in the literature. Medicine (Baltimore). 2004;83(6):348-359. doi: 10.1097/01.md.0000147737.57861.7cTomic-Lucic A, Petrovic R, Radak-Perovic M, Milovanovic D, Milovanovic J, Zivanovic S, et al. Late-onset systemic lupus erythematosus: Clinical features, course, and prognosis. Clin Rheumatol. 2013;32(7):1053-1058. doi: 10.1007/s10067-013-2238-yTomic-Lucic A, Petrovic R, Radak-Perovic M, Milovanovic D, Milovanovic J, Zivanovic S, et al. Late-onset systemic lupus erythematosus: Clinical features, course, and prognosis. Clin Rheumatol. 2013;32(7):1053-1058. doi: 10.1007/s10067-013-2238-yLalani S, Pope J, de Leon F, Peschken C; Members of CaNIOS/1000 Faces of Lupus. Clinical features and prognosis of lateonset systemic lupus erythematosus: results from the 1000 faces of lupus study. J Rheumatol. 2010;37(1):38-44. doi: 10.3899/jrheum.080957Lalani S, Pope J, de Leon F, Peschken C; Members of CaNIOS/1000 Faces of Lupus. Clinical features and prognosis of lateonset systemic lupus erythematosus: results from the 1000 faces of lupus study. J Rheumatol. 2010;37(1):38-44. doi: 10.3899/jrheum.080957Кошелева НМ, Алекберова ЗС, Насонова ВА, Карабаева АС. Системная красная волчанка: начало у лиц в возрасте старше 45 лет. Клиническая геронтология. 2002;3:16-21.Kosheleva NM, Alekberova ZS, Nasonova VA, Karabaeva AS. Systemic lupus erythematosus: Onset in people over 45 years of age. Clinical Gerontology. 2002;3:16-21 (In Russ.).Fernández M, Calvo-Alén J, Alarcón GS, Roseman JM, Bastian HM, Fessler BJ, et al. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): XXI. Disease activity, damage accrual, and vascular events in pre- and postmenopausal women. Arthritis Rheum. 2005;52(6):1655-1664. doi: 10.1002/art.21048Fernández M, Calvo-Alén J, Alarcón GS, Roseman JM, Bastian HM, Fessler BJ, et al. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): XXI. Disease activity, damage accrual, and vascular events in pre- and postmenopausal women. Arthritis Rheum. 2005;52(6):1655-1664. doi: 10.1002/art.21048Urowitz MB, Ibañez D, Jerome D, Gladman DD. The effect of menopause on disease activity in systemic lupus erythematosus. J Rheumatol. 2006;33(11):2192-2198.Urowitz MB, Ibañez D, Jerome D, Gladman DD. The effect of menopause on disease activity in systemic lupus erythematosus. J Rheumatol. 2006;33(11):2192-2198.Сухих ГТ, Сметник ВП, Андреева ЕН, Балан ВЕ, Гависова АА, Григорян ОР, и др. Менопаузальная гормонотерапия и сохранение здоровья женщин в зрелом возрасте. Проблемы репродукции. 2018;24(S6):727-756.Sukhikh GT, Smetnik VP, Andreeva EN, Balan VE, Gavisova AA, Grigoryan OR, et al. Menopausal hormone therapy and maintaining the health of women in adulthood. Russian Journal of Human Reproduction. 2018;24(S6):727-756 (In Russ.).Sammaritano L, Patterson K, Lockshin M, et al. Current use of estrogen replacement therapy in postmenopausal systemic lupus erythematosus patients: increase since inception of the SELENA trial. Arthritis Rheum. 1999;42(Suppl 9):197.Sammaritano L, Patterson K, Lockshin M, et al. Current use of estrogen replacement therapy in postmenopausal systemic lupus erythematosus patients: increase since inception of the SELENA trial. Arthritis Rheum. 1999;42(Suppl 9):197.Buyon JP, Kalunian KC, Skovron ML, Petri M, Lahita R, Merrill J, et al. Can women with systemic lupus erythematosus safely use exogenous estrogens? J Clin Rheumatol. 1995;1(4):205-212. doi: 10.1097/00124743-199508000-00002Buyon JP, Kalunian KC, Skovron ML, Petri M, Lahita R, Merrill J, et al. Can women with systemic lupus erythematosus safely use exogenous estrogens? J Clin Rheumatol. 1995;1(4):205-212. doi: 10.1097/00124743-199508000-00002Buyon JP, Wallace DL. The endocrine system, use of exogenous estrogens, and the urogenital tract. In: Wallace DJ, Hahn BJ (eds). Dubois’ lupus erythematosus; 5th ed. Baltimore:William et Wilkins; 1997:817-834.Buyon JP, Wallace DL. The endocrine system, use of exogenous estrogens, and the urogenital tract. In: Wallace DJ, Hahn BJ (eds). Dubois’ lupus erythematosus; 5th ed. Baltimore:William et Wilkins; 1997:817-834.Адамян ЛВ, Андреева ЕН, Аполихина ИА Артымук НВ, Ашрафян ЛА, Балан ВЕ, и др. Менопауза и климактерическое состояние у женщины: клинические рекомендации. М.;2021.Adamyan LV, Andreeva EN, Apolikhina IA Artymuk NV, Ashrafyan LA, Balan VE, et al. Menopause and menopause in women: Clinical guidelines. Moscow; 2021 (In Russ.).Holroyd CR, Edwards CJ. The effects of hormone replacement therapy on autoimmune disease: Rheumatoid arthritis and systemic lupus erythematosus. Climacteric. 2009;12(5):378-386. doi: 10.1080/13697130903025449Holroyd CR, Edwards CJ. The effects of hormone replacement therapy on autoimmune disease: Rheumatoid arthritis and systemic lupus erythematosus. Climacteric. 2009;12(5):378-386. doi: 10.1080/13697130903025449Gompel A. Systemic lupus erythematosus and menopause. Climacteric. 2020;23(2):109-115. doi: 10.1080/13697137.2019.1679113Gompel A. Systemic lupus erythematosus and menopause. Climacteric. 2020;23(2):109-115. doi: 10.1080/13697137.2019.1679113Gompel A, Piette JC. Systemic lupus erythematosus and hormone replacement therapy. Menopause Int. 2007;13(2):65-70. doi: 10.1258/175404507780796433Gompel A, Piette JC. Systemic lupus erythematosus and hormone replacement therapy. Menopause Int. 2007;13(2):65-70. doi: 10.1258/175404507780796433Sánchez-Guerrero J, Liang MH, Karlson EW, Hunter DJ, Colditz GA. Postmenopausal estrogen therapy and the risk for developing systemic lupus erythematosus. Ann Intern Med. 1995;122(6): 430-433. doi: 10.7326/0003-4819-122-6-199503150-00005Sánchez-Guerrero J, Liang MH, Karlson EW, Hunter DJ, Colditz GA. Postmenopausal estrogen therapy and the risk for developing systemic lupus erythematosus. Ann Intern Med. 1995;122(6): 430-433. doi: 10.7326/0003-4819-122-6-199503150-00005Meier CR, Sturkenboom MC, Cohen AS, Jick H. Postmenopausal estrogen replacement therapy and the risk of developing systemic lupus erythematosus or discoid lupus. J Rheumatol. 1998;25(8): 1515-1519.Meier CR, Sturkenboom MC, Cohen AS, Jick H. Postmenopausal estrogen replacement therapy and the risk of developing systemic lupus erythematosus or discoid lupus. J Rheumatol. 1998;25(8): 1515-1519.Costenbader KH, Feskanich D, Stampfer MJ, Karlson EW. Reproductive and menopausal factors and risk of systemic lupus erythematosus in women. Arthritis Rheum. 2007;56(4):1251-1262. doi: 10.1002/art.22510Costenbader KH, Feskanich D, Stampfer MJ, Karlson EW. Reproductive and menopausal factors and risk of systemic lupus erythematosus in women. Arthritis Rheum. 2007;56(4):1251-1262. doi: 10.1002/art.22510Buyon JP, Petri MA, Kim MY, Kalunian KC, Grossman J, Hahn BH, et al. The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: A randomized trial. Ann Intern Med. 2005; 142(12 Pt 1):953-962. doi: 10.7326/0003-4819-142-12_part_1-200506210-00004Buyon JP, Petri MA, Kim MY, Kalunian KC, Grossman J, Hahn BH, et al. The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: A randomized trial. Ann Intern Med. 2005; 142(12 Pt 1):953-962. doi: 10.7326/0003-4819-142-12_part_1-200506210-00004Sánchez-Guerrero J, González-Pérez M, Durand-Carbajal M, Lara-Reyes P, Jiménez-Santana L, Romero-Díaz J, et al. Menopause hormonal therapy in women with systemic lupus erythematosus. Arthritis Rheum. 2007;56(9):3070-3079. doi: 10.1002/art.22855Sánchez-Guerrero J, González-Pérez M, Durand-Carbajal M, Lara-Reyes P, Jiménez-Santana L, Romero-Díaz J, et al. Menopause hormonal therapy in women with systemic lupus erythematosus. Arthritis Rheum. 2007;56(9):3070-3079. doi: 10.1002/art.22855Arden NK, Lloyd ME, Spector TD, Hughes GR. Safety of hormone replacement therapy (HRT) in systemic lupus erythematosus (SLE). Lupus. 1994;3(1):11-13. doi: 10.1177/096120339400300104Arden NK, Lloyd ME, Spector TD, Hughes GR. Safety of hormone replacement therapy (HRT) in systemic lupus erythematosus (SLE). Lupus. 1994;3(1):11-13. doi: 10.1177/096120339400300104Kreidstein S, Urowitz MB, Gladman DD, Gough J. Hormone replacement therapy in systemic lupus erythematosus. J Rheumatol. 1997;24(11):2149-2152.Kreidstein S, Urowitz MB, Gladman DD, Gough J. Hormone replacement therapy in systemic lupus erythematosus. J Rheumatol. 1997;24(11):2149-2152.Mok CC, Lau CS, Ho CT, Lee KW, Mok MY, Wong RW. Safety of hormonal replacement therapy in postmenopausal patients with systemic lupus erythematosus. Scand J Rheumatol. 1998; 27(5):342-346. doi: 10.1080/03009749850154357Mok CC, Lau CS, Ho CT, Lee KW, Mok MY, Wong RW. Safety of hormonal replacement therapy in postmenopausal patients with systemic lupus erythematosus. Scand J Rheumatol. 1998; 27(5):342-346. doi: 10.1080/03009749850154357Rojas-Villarraga A, Torres-Gonzalez JV, Ruiz-Sternberg ÁM. Safety of hormonal replacement therapy and oral contraceptives in systemic lupus erythematosus: A systematic review and metaanalysis. PLoS One. 2014;9(8):e104303. doi: 10.1371/journal.pone.0104303Rojas-Villarraga A, Torres-Gonzalez JV, Ruiz-Sternberg ÁM. Safety of hormonal replacement therapy and oral contraceptives in systemic lupus erythematosus: A systematic review and metaanalysis. PLoS One. 2014;9(8):e104303. doi: 10.1371/journal.pone.0104303Sanches-Guerrero J, Romero-Diaz J, Mendoza-Fuentes A, Mendoza-Peralta M, del Carmen Cravioto M. Menopause in systemic lupus erythematosus. Age at menopause and clinical characteristics. Arthritis Rheum. 1999;42(Suppl 9):205.Sanches-Guerrero J, Romero-Diaz J, Mendoza-Fuentes A, Mendoza-Peralta M, del Carmen Cravioto M. Menopause in systemic lupus erythematosus. Age at menopause and clinical characteristics. Arthritis Rheum. 1999;42(Suppl 9):205.Alpízar-Rodríguez D, Romero-Díaz J, Sánchez-Guerrero J, Seuc AH, Cravioto Mdel C. Age at natural menopause among patients with systemic lupus erythematosus. Rheumatology (Oxford). 2014;53(11):2023-2029. doi: 10.1093/rheumatology/keu222Alpízar-Rodríguez D, Romero-Díaz J, Sánchez-Guerrero J, Seuc AH, Cravioto Mdel C. Age at natural menopause among patients with systemic lupus erythematosus. Rheumatology (Oxford). 2014;53(11):2023-2029. doi: 10.1093/rheumatology/keu222González LA, Pons-Estel GJ, Zhang JS, McGwin G Jr, Roseman J, Reveille JD, et al.; LUMINA Study Group. Effect of age, menopause and cyclophosphamide use on damage accrual in systemic lupus erythematosus patients from LUMINA, a multiethnic US cohort (LUMINA LXIII). Lupus. 2009;18(2):184-186. doi: 10.1177/0961203308098988González LA, Pons-Estel GJ, Zhang JS, McGwin G Jr, Roseman J, Reveille JD, et al.; LUMINA Study Group. Effect of age, menopause and cyclophosphamide use on damage accrual in systemic lupus erythematosus patients from LUMINA, a multiethnic US cohort (LUMINA LXIII). Lupus. 2009;18(2):184-186. doi: 10.1177/0961203308098988Morel N, Bachelot A, Chakhtoura Z, Ghillani-Dalbin P, Amoura Z, Galicier L, et al.; PLUS group. Study of anti-Müllerian hormone and its relation to the subsequent probability of pregnancy in 112 patients with systemic lupus erythematosus, exposed or not to cyclophosphamide. J Clin Endocrinol Metab. 2013;98(9):3785-3792. doi: 10.1210/jc.2013-1235Morel N, Bachelot A, Chakhtoura Z, Ghillani-Dalbin P, Amoura Z, Galicier L, et al.; PLUS group. Study of anti-Müllerian hormone and its relation to the subsequent probability of pregnancy in 112 patients with systemic lupus erythematosus, exposed or not to cyclophosphamide. J Clin Endocrinol Metab. 2013;98(9):3785-3792. doi: 10.1210/jc.2013-1235Lawrenz B, Henes J, Henes M, Neunhoeffer E, Schmalzing M, Fehm T, et al. Impact of systemic lupus erythematosus on ovarian reserve in premenopausal women: Evaluation by using anti-Muellerian hormone. Lupus. 2011;20(11):1193-1197. doi: 10.1177/0961203311409272Lawrenz B, Henes J, Henes M, Neunhoeffer E, Schmalzing M, Fehm T, et al. Impact of systemic lupus erythematosus on ovarian reserve in premenopausal women: Evaluation by using anti-Muellerian hormone. Lupus. 2011;20(11):1193-1197. doi: 10.1177/0961203311409272Marder W, McCune WJ, Wang L, Wing JJ, Fisseha S, McConnell DS, et al. Adjunctive GnRH-a treatment attenuates depletion of ovarian reserve associated with cyclophosphamide therapy in premenopausal SLE patients. Gynecol Endocrinol. 2012;28(8):624-627. doi: 10.3109/09513590.2011.650752Marder W, McCune WJ, Wang L, Wing JJ, Fisseha S, McConnell DS, et al. Adjunctive GnRH-a treatment attenuates depletion of ovarian reserve associated with cyclophosphamide therapy in premenopausal SLE patients. Gynecol Endocrinol. 2012;28(8):624-627. doi: 10.3109/09513590.2011.650752Mok CC, Lau CS, Wong RW. Risk factors for ovarian failure in patients with systemic lupus erythematosus receiving cyclophosphamide therapy. Arthritis Rheum. 1998;41(5):831-837. doi: 10.1002/1529-0131(199805)41:5<831::AID-ART9>3.0.CO;2-1Mok CC, Lau CS, Wong RW. Risk factors for ovarian failure in patients with systemic lupus erythematosus receiving cyclophosphamide therapy. Arthritis Rheum. 1998;41(5):831-837. doi: 10.1002/1529-0131(199805)41:5<831::AID-ART9>3.0.CO;2-1Wajed J, Ahmad Y, Durrington PN, Bruce IN. Prevention of cardiovascular disease in systemic lupus erythematosus – Proposed guidelines for risk factor management. Rheumatology (Oxford). 2004;43(1):7-12. doi: 10.1093/rheumatology/keg436Wajed J, Ahmad Y, Durrington PN, Bruce IN. Prevention of cardiovascular disease in systemic lupus erythematosus – Proposed guidelines for risk factor management. Rheumatology (Oxford). 2004;43(1):7-12. doi: 10.1093/rheumatology/keg436Bruce IN, Urowitz MB, Gladman DD, Ibañez D, Steiner G. Risk factors for coronary heart disease in women with systemic lupus erythematosus: The Toronto Risk Factor Study. Arthritis Rheum. 2003;48(11):3159-3167. doi: 10.1002/art.11296Bruce IN, Urowitz MB, Gladman DD, Ibañez D, Steiner G. Risk factors for coronary heart disease in women with systemic lupus erythematosus: The Toronto Risk Factor Study. Arthritis Rheum. 2003;48(11):3159-3167. doi: 10.1002/art.11296Попкова ТВ, Алекберова ЗС, Александрова ЕН, Булгакова ОВ, Насонов ЕЛ. Факторы риска кардиоваскулярных нарушений и атеросклероза при системной красной волчанке. Научно-практическая ревматология. 2004;42(4):10-14.Popkova TV, Alekberova ZS, Aleksandrova EN, Bulgakova OK, Nassonov EL. Cardiovascular disturbances and atherosclerosis risk factors in systemic lupus erythematosus. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2004;42(4):10-14 (In Russ.).Doria A, Iaccarino L, Sarzi-Puttini P, Atzeni F, Turriel M, Petri M. Cardiac involvement in systemic lupus erythematosus. Lupus. 2005;14(9):683-686. doi: 10.1191/0961203305lu2200oaDoria A, Iaccarino L, Sarzi-Puttini P, Atzeni F, Turriel M, Petri M. Cardiac involvement in systemic lupus erythematosus. Lupus. 2005;14(9):683-686. doi: 10.1191/0961203305lu2200oaRibeiro GG, Bonfá E, Sasdeli Neto R, Abe J, Caparbo VF, Borba EF, et al. Premature coronary artery calcification is associated with disease duration and bone mineral density in young female systemic lupus erythematosus patients. Lupus. 2010;19(1):27-33. doi: 10.1177/0961203309345778Ribeiro GG, Bonfá E, Sasdeli Neto R, Abe J, Caparbo VF, Borba EF, et al. Premature coronary artery calcification is associated with disease duration and bone mineral density in young female systemic lupus erythematosus patients. Lupus. 2010;19(1):27-33. doi: 10.1177/0961203309345778Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al.; Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288(3):321-333. doi: 10.1001/jama.288.3.321Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al.; Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288(3):321-333. doi: 10.1001/jama.288.3.321Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA. 1998;280(7):605-613. doi: 10.1001/jama.280.7.605Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA. 1998;280(7):605-613. doi: 10.1001/jama.280.7.605Anagnostis P, Lambrinoudaki I, Stevenson JC, Goulis DG. Meno pause-associated risk of cardiovascular disease. Endocr Connect. 2022;11(4):e210537. doi: 10.1530/EC-21-0537Anagnostis P, Lambrinoudaki I, Stevenson JC, Goulis DG. Meno pause-associated risk of cardiovascular disease. Endocr Connect. 2022;11(4):e210537. doi: 10.1530/EC-21-0537Hochman J, Urowitz MB, Ibañez D, Gladman DD. Hormone replacement therapy in women with systemic lupus erythematosus and risk of cardiovascular disease. Lupus. 2009;18(4):313-317. doi: 10.1177/0961203308097475Hochman J, Urowitz MB, Ibañez D, Gladman DD. Hormone replacement therapy in women with systemic lupus erythematosus and risk of cardiovascular disease. Lupus. 2009;18(4):313-317. doi: 10.1177/0961203308097475Singh NK, Agrawal A, Singh MN, Kumar V, Godhra M, Gupta A, et al. Prevalence and pattern of antiphospholipid antibody syndrome in a hospital based longitudinal study of 193 patients of systemic lupus erythematosus. J Assoc Physicians India. 2013;61(9):623-626.Singh NK, Agrawal A, Singh MN, Kumar V, Godhra M, Gupta A, et al. Prevalence and pattern of antiphospholipid antibody syndrome in a hospital based longitudinal study of 193 patients of systemic lupus erythematosus. J Assoc Physicians India. 2013;61(9):623-626.Gris JC, Bourguignon C, Bouvier S, Nouvellon É, Laurent J, Perez-Martin A, et al. Combined oral contraceptive-associated venous thromboembolism revealing an antiphospholipid syndrome: International retrospective study of outcomes. Thromb Res. 2022;219:102-108. doi: 10.1016/j.thromres.2022.09.013Gris JC, Bourguignon C, Bouvier S, Nouvellon É, Laurent J, Perez-Martin A, et al. Combined oral contraceptive-associated venous thromboembolism revealing an antiphospholipid syndrome: International retrospective study of outcomes. Thromb Res. 2022;219:102-108. doi: 10.1016/j.thromres.2022.09.013Крюков ЕВ, Паневин ТС. Антитромбогенная активность сосудистой стенки в период пери- и постменопаузы у женщин с климактерической миокардиодистрофией. Вестник национального медико-хирургического центра им. Н.И. Пирогова. 2020;15(2):67-70. doi: 10.25881/BPNMSC.2020.26.26.010Kryukov EV, Panevin TS. Antithrombogenic vessel wall activity in women with climacteric myocardiodys trophy during the period of peri- and postmenopause. Bulletin of Pirogov National Medical & Surgical Center. 2020;15(2):67-70 (In Russ.). doi: 10.25881/BPNMSC.2020.26.26.010Крюков ЕВ, Паневин ТС, Попова ЛВ. Возрастные изменения системы гемостаза. Клиническая медицина. 2020;98(1):9-1. doi: 10.34651/0023-2149-2020-98-1-9-12Kryukov EV, Panevin TS, Popova LV. Age-related changes in the hemostasis system. Clinical Medicine (Russian Journal). 2020;98(1):9-12 (In Russ.) doi: 10.34651/0023-2149-2020-98-1-9-12Крюков ЕВ, Попова ЛВ, Васильев СВ, Паневин ТС, Паневина АС, Стромская УА, и др. Ультранизкодозированная менопаузальная гормонотерапия с дидрогестероном: роль в профилактике развития и прогрессирования атеросклероза. Вестник Российской военно-медицинской академии. 2021;1(73):9-14. doi: 10.17816/brmma63562Kryukov EV, Popova LV, Vasiliev SV, Panevin TS, Panevina AS, Stromskaya UA, et al. Ultra-low dose estradiol plus dydrogesterone: A role in prevention of the development and progression of atherosclerosis. Bulletin of the Russian Military Medical Academy. 2021;23(1):9-14 (In Russ.). doi: 10.17816/brmma63562Ramsey-Goldman R, Mattai SA, Schilling E, Chiu YL, Alo CJ, Howe HL, et al. Increased risk of malignancy in patients with systemic lupus erythematosus. J Investig Med. 1998;46(5):217-222.Ramsey-Goldman R, Mattai SA, Schilling E, Chiu YL, Alo CJ, Howe HL, et al. Increased risk of malignancy in patients with systemic lupus erythematosus. J Investig Med. 1998;46(5):217-222.Bernatsky S, Boivin JF, Joseph L, Manzi S, Ginzler E, Gladman DD, et al. Mortality in systemic lupus erythematosus. Arthritis Rheum. 2006;54(8):2550-2557. doi: 10.1002/art.21955Bernatsky S, Boivin JF, Joseph L, Manzi S, Ginzler E, Gladman DD, et al. Mortality in systemic lupus erythematosus. Arthritis Rheum. 2006;54(8):2550-2557. doi: 10.1002/art.21955Sammaritano LR, Bermas BL, Chakravarty EE, Chambers C, Clowse MEB, Lockshin MD, et al. 2020 American College of Rheumatology guideline for the management of reproductive health in rheumatic and musculoskeletal diseases. Arthritis Rheumatol. 2020;72(4):529-556. doi: 10.1002/art.41191Sammaritano LR, Bermas BL, Chakravarty EE, Chambers C, Clowse MEB, Lockshin MD, et al. 2020 American College of Rheumatology guideline for the management of reproductive health in rheumatic and musculoskeletal diseases. Arthritis Rheumatol. 2020;72(4):529-556. doi: 10.1002/art.41191Andreoli L, Bertsias GK, Agmon-Levin N, Brown S, Cervera R, Costedoat-Chalumeau N, et al. EULAR recommendations for women’s health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. Ann Rheum Dis. 2017;76(3):476-485. doi: 10.1136/annrheumdis-2016-209770Andreoli L, Bertsias GK, Agmon-Levin N, Brown S, Cervera R, Costedoat-Chalumeau N, et al. EULAR recommendations for women’s health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. Ann Rheum Dis. 2017;76(3):476-485. doi: 10.1136/annrheumdis-2016-209770

The authors declare that there are no conflicts of interest present.